SU2C to host roadblock televised fundraising special Aug. 21

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Stand Up To Cancer will hold its seventh biennial roadblock televised fundraising special August 21. 

This year’s show will air on Saturday, Aug. 21 at 8 p.m. ET & PT / 7 p.m. CT. Reese Witherspoon and Jim Toth, a media industry entrepreneur and investor, will come on board as co-executive producers, working alongside the renowned live-event producing team Done + Dusted and Stand Up To Cancer’s production team. 

Anthony Anderson, Ken Jeong & Tran Ho, and Sofia Vergara will also join as cohosts. Common and Brittany Howard are the first of many to be announced as performers during the special evening.

Stand Up To Cancer’s biennial special will broadcast from Los Angeles and air simultaneously on more than 60 participating media platforms across the United States and Canada, including all four major broadcast networks in the U.S. Broadcasters carrying the show are donating one hour of simultaneous commercial-free prime time. The telecast will also be available to stream live and on-demand on several streaming platforms.

SU2C’s biennial specials have been supported by hundreds of celebrities over the past 13 years. The names of participants, as well as additional musical performers, for the 2021 special will be announced in the weeks leading up to the telecast.

Table of Contents

YOU MAY BE INTERESTED IN

George F. Tidmarsh has resigned from his job as director of the FDA Center for Drug Evaluation and Research in the aftermath of a lawsuit by a former associate and a probe into what an HHS spokesperson described as “serious concerns about his personal conduct.”
Research has shown that delivering tumor profiling results to cancer patients prior to initiation of treatment and connecting patients harboring an actionable oncogenic mutation with the right targeted therapy can deliver superior patient outcomes. To fulfill this promise of precision medicine, we need to ensure more targeted therapies are available to patients who need them. Fortunately, this work is well underway. xxx:more

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login